Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Phase 4

Completed

Conditions: Hearth Failure With Reduced Ejection Fraction (HFrEF)

Interventions: Drug: LCZ696 (sacubitril/valsartan)

First Posted Date: 2016-02-24

Last Posted Date: 2019-06-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT02690974

Locations: 🇨🇦
Novartis Investigative Site, St-Lambert, Canada

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Phase 4

Completed

Conditions: Chronic Plaque Psoriasis

Interventions: Drug: Secukinumab 300 mg
Biological: Placebo

First Posted Date: 2016-02-24

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 91

Registration Number: NCT02690701

Locations: 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Phase 2

Completed

Conditions: Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Pleomorphic Xanthoastrocytoma
Angiocentric Glioma
Giant Cell Astrocytoma
Anaplastic Pleomorphic Xanthoastrocytoma
Oligodendroglioma, Childhood
Glioblastoma
Astrocytoma
Pilocytic Astrocytoma

Interventions: Drug: Dabrafenib
Drug: Carboplatin
Drug: trametinib
Drug: Vincristine

First Posted Date: 2016-02-17

Last Posted Date: 2023-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 151

Registration Number: NCT02684058

Locations: 🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago, Illinois, United States
🇺🇸
Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States

and more 8 locations

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Phase 1

Completed

Conditions: Advanced Malignancies

Interventions: Drug: PDR001

First Posted Date: 2016-02-09

Last Posted Date: 2018-06-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT02678260

Locations: 🇯🇵
Novartis Investigative Site, Kobe-city, Hyogo, Japan

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

Phase 2

Completed

Conditions: Chronic Kidney Disease (CKD)

Interventions: Drug: Placebo
Drug: LHW090

First Posted Date: 2016-02-09

Last Posted Date: 2021-10-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT02678000

Locations: 🇩🇪
Novartis Investigative Site, Mannheim, Germany

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Phase 2

Completed

Conditions: Pediatric Heart Failure

Interventions: Drug: LCZ696
Drug: Enalapril
Drug: Placebo of Enalapril
Drug: Placebo of LCZ696

First Posted Date: 2016-02-09

Last Posted Date: 2023-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 393

Registration Number: NCT02678312

Locations: 🇹🇷
Novartis Investigative Site, Konak, Turkey

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: VAY736 placebo
Biological: VAY736

First Posted Date: 2016-02-05

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT02675803

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Phase 2

Withdrawn

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2016-02-03

Last Posted Date: 2018-08-10

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02672358

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Behavioral: Lifestyle intervention

First Posted Date: 2016-02-02

Last Posted Date: 2019-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 130

Registration Number: NCT02670928

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: AIN457 (secukinumab)
Drug: Placebo

First Posted Date: 2016-01-26

Last Posted Date: 2021-12-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 166

Registration Number: NCT02662985

Locations: 🇬🇧
Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy